GlassScriptPhysician profile
Jimmy D Alele
NPI 1447368311
$1,884.06
in general payments reported to CMS, 2019-2025
28 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $277 · 2021: $13.78 · 2022: $201 · 2023: $33.89 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $518.10 | 2019-2025 | Evenity, Tepezza |
| Novo Nordisk INC | $283.31 | 2019-2025 | Ozempic |
| Tandem Diabetes Care, INC. | $176.98 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $135.79 | 2019-2022 | |
| Dexcom, INC. | $105.29 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $99.68 | 2019-2020 | |
| Insulet Corporation | $85.67 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $53.08 | 2019-2022 | |
| Lifescan, INC. | $46.86 | 2019 | |
| Sequel Med Tech, LLC | $46.38 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $44.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.78 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.45 | 2022 | |
| Abbvie INC. | $25.51 | 2019 | |
| Merck Sharp & Dohme LLC | $23.90 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $22.62 | 2019 | |
| Ascensia Diabetes Care US INC. | $19.02 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.86 | 2025 | Recorlev |
| Abbott Laboratories | $16.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.20 | 2022 | |
| Lilly USA, LLC | $12.71 | 2022 | |
| Zealand Pharma US, INC. | $12.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.80 | 2022 | |
| Alfasigma USA, INC. | $11.73 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.67 | 2022 | |
| Valeritas, INC. | $11.07 | 2019 | |
| Amarin Pharma, INC. | $10.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Alele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.